跳至主要内容
临床试验/DRKS00014825
DRKS00014825已完成不适用

Multicentre Non-interventional Study of Treatment Outcome in Heart Failure Patients with Hyperkalaemia under RAASi-treatment Receiving Veltassa in Routine Practice - CONTINUE-HF NIS

Vifor Pharma Deutschland GmbH0 个研究点目标入组 22 人开始时间: 2018年6月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • •1. 18 years or older
  • •2. signed informed consent
  • •3. heart failure with left ventricular ejection fraction less than 40%
  • •4. with or without chronic renal insufficiency
  • •5. therapy with inhibitors of the renin-angiotensin-aldosterone-system (RAASi)
  • •6. hyperkalemia (serum potassium values equal/higher than 5.1 mmol/L at baseline that limits ability to maintain or increase the dose of RAASi
  • •7. scheduled for treatment with Veltassa as per label

排除标准

  • •1. current dialysis or anticipated during study participation
  • •2. type I diabetes mellitus
  • •3. acute kidney injury
  • •4. cancer with less than 12 months life expectancy
  • •5. heart or kidney transplantation or anticipated during study participation
  • •6. investigational medication currently, 21 days or 5 half-lives prior to baseline
  • •7. inability to consume Veltassa
  • •8. severe medical condition currently or in the last 21 days prior baseline which could decrease study compliance or jeopardize the safety of the patient.

研究者

相似试验